)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Double Bond Pharmaceutical
Double Bond Pharmaceutical (DBP) investor relations material
Double Bond Pharmaceutical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Ongoing negotiations with four potential partners, including two pharmaceutical companies and two financial investors, focused on Temodex and SI053 products.
Preparing a supplementary cohort analysis based on MGMT status to strengthen RWE study evidence for Temodex.
Active preparations for major medical congress presentations and commercialization of Temodex in Turkey, China, and Mexico.
Financial highlights
Total revenue for Q2 2026 and H1 2026 was 0.0 MSEK, unchanged year-over-year.
Operating loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 operating loss was -0.9 MSEK (vs. -0.8 MSEK H1 2025).
Net loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 net loss was -0.9 MSEK (improved from -1.5 MSEK H1 2025).
Earnings per share for H1 2026 was -0.00 SEK (vs. -0.02 SEK H1 2025).
Cash and cash equivalents at June 30, 2026, were 239,519 SEK (vs. 255,067 SEK June 30, 2025).
Outlook and guidance
Focus remains on advancing negotiations, completing the MGMT cohort analysis, maximizing congress presence, and commercializing Temodex in key markets.
Next financial report scheduled for November 25, 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Double Bond Pharmaceutical
- Q1 2026 delivered narrowed losses and major clinical validation for Temodex.DBP
Q1 2026 - Breakthroughs in SI053/Temodex and improved financials position for future growth.DBPQ4 2025
- Improved results and restored equity as S1053 advances toward potential partnerships.DBPQ3 2025
- Revenue and net loss improved, with strong project progress and a major rights issue launched.DBPQ2 2025
- SI-053 clinical trial preparations advanced, with improved results and new financing secured.DBPQ3 2024
- SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus.DBPQ2 2024
- Losses narrowed as SI-053 advanced; funding secured, liquidity sufficient into Q3 2025.DBPQ4 2024
- Revenues rose and losses narrowed as SI053 clinical trial preparations were completed.DBPQ1 2025
Next Double Bond Pharmaceutical earnings date
Q3 202613 Nov, 2026
Double Bond Pharmaceutical
Next Double Bond Pharmaceutical earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage